Replies to post #207805 on Biotech Values

[poorgradstudent]

INCY / IO etc...

So you get that multiplicative effect of increasing the value of existing IO drug(s) that may have high efficacy like a PD-1 even with an add on drug that increases efficacy only a little bit, since that combo can now be differentiated from the crowd (even modestly so)

This was my view of the IDO thesis, especially from the viewpoint of a company like INCY. Get on the market, because fractional increases in efficacy matter and can be improved upon. Holding out for / expecting home runs is a poor strategy.

Going forward, I do think the market is going to pay increased attention to drugs that bring incremental benefit in the IO space, especially due to the competition between the pharma companies. Others can correct me but I don't think I've ever seen the oncology space this competitive with this many large pharma companies simultaneously trying to develop drugs against the same targets (especially IO ones). In that regard, seeing if an add-on like INCY's IDOi improves the competitive edge of your PD-1 (for example) is a no-brainer.


Edit: My previous post had incorrectly stated 2016. I meant 2015.